CBAY News and Press, CymaBay Therapeutics Inc. From 11/03/21

NEWARK, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live aud...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips While never entirely out of fashion, penny stocks are drawing new-found attention from retail investors. One reason for this interest is that many new traders see the penny stock market as a way of turning a small investm...

NEWARK, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that multiple presentations of resu...

Image source: The Motley Fool. CymaBay Therapeutics Inc. (NASDAQ: CBAY) Q2 2021 Earnings Call Aug 12, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: CymaBay Therapeutics Inc. (CBAY) Q2 2021 Earnings Call Transcript...

CymaBay Therapeutics, Inc. (CBAY) Q2 2021 Earnings Conference Call August 12, 2021 04:30 PM ET Company Participants Dan Menold - Vice President, Finance Sujal Shah - Chief Executive Officer Dennis Kim - Chief Medical Officer Chuck McWherter - Chief Scientific Officer Conference Call Participa...

Secured up to $100 million of additional development funding through a non-dilutive financing transaction with Abingworth Funds the Phase 3 development program for seladelpar in primary biliary cholangitis (PBC), including the Phase 3 RESPONSE clinical trial Active...

NEWARK, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live aud...

CymaBay Therapeutics (NASDAQ:CBAY) announced a $100M non-dilutive financing from Abingworth aimed at the Phase 3 development of liver disease drug seladelpar. The funding will be earmarked for Phase 3 program of seladelpar in primary biliary cholangitis (PBC) including the Phase 3 RESPON...

Risk-sharing agreement with Abingworth will fund seladelpar Phase 3 development program for PBC CymaBay retains full worldwide commercial rights to seladelpar NEWARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biop...

New analyses adds to the growing body of evidence for seladelpar’s potential as a treatment for patients with PBC NEWARK, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on develop...